GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as repla

Trial Details

NCT ID
NCT05695508
Phase
PHASE2
Sponsor
University of Heidelberg Medical Center
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Teclistamab (Tec)
  • Daratumumab
  • Dexamethasone
  • Lenalidomide
  • Bortezomib
  • Talquetamab
Locations (sample)
  • Berlin, Germany|52.52437,13.41053
  • Chemnitz, Germany|50.8357,12.92922
  • Dresden, Germany|51.05089,13.73832
  • Düsseldorf, Germany|51.22172,6.77616
  • Freiburg im Breisgau, Germany|47.9959,7.85222

Key Eligibility Criteria

  • \- 18 years of age to 70 years of age, inclusive
  • Have an ECOG performance status score of 0 to 2 at screening
  • Have an ECOG performance status score of 0 to 2 at screening and immediately prior to the start of administration of study treatment
  • Participants in Arms A, A1, B, D, E, E1, F, F1 and G must also satisfy all of the following criteria to be enrolled in the study:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →